Skandinaviska Enskilda Banken (SEB)’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $709K | Sell |
7,836
-8,946
| -53% | -$749K | 0.03% | 90 |
|
|
2026
Q1 | $1.34M | Sell |
16,782
-1,049,424
| -98% | -$86.5M | 0.03% | 92 |
|
|
2025
Q4 | $90.9M | Sell |
1,066,206
-17,086
| -2% | -$1.4M | 0.36% | 51 |
|
|
2025
Q3 | $84.2M | Sell |
1,083,292
-6,759
| -0.6% | -$528K | 0.34% | 60 |
|
|
2025
Q2 | $85.3M | Buy |
1,090,051
+143,603
| +15% | +$10.7M | 0.37% | 53 |
|
|
2025
Q1 | $68.6M | Sell |
946,448
-2,626
| -0.3% | -$188K | 0.34% | 56 |
|
|
2024
Q4 | $70.5M | Buy |
949,074
+56,051
| +6% | +$3.92M | 0.32% | 54 |
|
|
2024
Q3 | $58.9M | Buy |
893,023
+420,128
| +89% | +$30.5M | 0.27% | 65 |
|
|
2024
Q2 | $43.7M | Buy |
472,895
+111,605
| +31% | +$9.88M | 0.21% | 84 |
|
|
2024
Q1 | $34.5M | Sell |
361,290
-23,231
| -6% | -$1.95M | 0.17% | 113 |
|
|
2023
Q4 | $29.3M | Sell |
384,521
-76,466
| -17% | -$5.32M | 0.17% | 120 |
|
|
2023
Q3 | $31.9M | Sell |
460,987
-61,684
| -12% | -$4.96M | 0.21% | 93 |
|
|
2023
Q2 | $49.3M | Buy |
522,671
+223,132
| +74% | +$19.4M | 0.32% | 63 |
|
|
2023
Q1 | $24.8M | Sell |
299,539
-268,044
| -47% | -$21.1M | 0.17% | 127 |
|
|
2022
Q4 | $42.3M | Sell |
567,583
-22,872
| -4% | -$1.76M | 0.32% | 80 |
|
|
2022
Q3 | $48.8M | Buy |
590,455
+25,225
| +4% | +$2.43M | 0.38% | 62 |
|
|
2022
Q2 | $53.7M | Buy |
565,230
+251,037
| +80% | +$26M | 0.4% | 63 |
|
|
2022
Q1 | $37M | Sell |
314,193
-228,794
| -42% | -$25.7M | 0.22% | 96 |
|
|
2021
Q4 | $71M | Sell |
542,987
-3,760
| -0.7% | -$439K | 0.37% | 53 |
|
|
2021
Q3 | $61.9M | Buy |
546,747
+26,799
| +5% | +$3.06M | 0.34% | 71 |
|
|
2021
Q2 | $53.9M | Sell |
519,948
-53,910
| -9% | -$5.08M | 0.33% | 67 |
|
|
2021
Q1 | $48M | Sell |
573,858
-206,353
| -26% | -$17.4M | 0.32% | 68 |
|
|
2020
Q4 | $71.2M | Sell |
780,211
-27,454
| -3% | -$2.28M | 0.49% | 39 |
|
|
2020
Q3 | $64.5M | Sell |
807,665
-175
| -0% | -$13.7K | 0.47% | 47 |
|
|
2020
Q2 | $55.8M | Sell |
807,840
-85,527
| -10% | -$6.08M | 0.45% | 50 |
|
|
2020
Q1 | $56.2M | Buy |
893,367
+61,854
| +7% | +$4.46M | 0.57% | 37 |
|
|
2019
Q4 | $64.7M | Buy |
831,513
+638,460
| +331% | +$49.9M | 0.51% | 45 |
|
|
2019
Q3 | $14.2M | Buy |
193,053
+68,394
| +55% | +$4.8M | 0.12% | 159 |
|
|
2019
Q2 | $7.68M | Buy |
124,659
+5,403
| +5% | +$327K | 0.07% | 253 |
|
|
2019
Q1 | $7.61M | Sell |
119,256
-2,274
| -2% | -$130K | 0.07% | 224 |
|
|
2018
Q4 | $6.21M | Buy |
121,530
+14,028
| +13% | +$710K | 0.06% | 243 |
|
|
2018
Q3 | $6.24M | Sell |
107,502
-3,900
| -4% | -$191K | 0.05% | 258 |
|
|
2018
Q2 | $5.41M | Buy |
111,402
+33,426
| +43% | +$1.56M | 0.05% | 264 |
|
|
2018
Q1 | $3.63M | Sell |
77,976
-38,103
| -33% | -$1.65M | 0.03% | 276 |
|
|
2017
Q4 | $4.36M | Sell |
116,079
-168,051
| -59% | -$6.17M | 0.04% | 300 |
|
|
2017
Q3 | $10.4M | Buy |
284,130
+176,400
| +164% | +$6.73M | 0.09% | 182 |
|
|
2017
Q2 | $4.25M | Buy |
107,730
+2,700
| +3% | +$98.6K | 0.04% | 326 |
|
|
2017
Q1 | $3.29M | Sell |
105,030
-258,768
| -71% | -$8.1M | 0.03% | 357 |
|
|
2016
Q4 | $11.4M | Sell |
363,798
-740,295
| -67% | -$24M | 0.14% | 130 |
|
|
2016
Q3 | $44.4M | Sell |
1,104,093
-101,700
| -8% | -$3.83M | 0.48% | 43 |
|
|
2016
Q2 | $40.1M | Buy |
1,205,793
+3,300
| +0.3% | +$113K | 0.45% | 46 |
|
|
2016
Q1 | $35.4M | Buy |
+1,202,493
| New | +$33.2M | 0.4% | 51 |
|
Other funds holding EW
Skandinaviska Enskilda Banken (SEB)'s EW Position: Q2 2026 in Review
Skandinaviska Enskilda Banken (SEB) reduced its Edwards Lifesciences (EW) stake by 53% in Q2 2026, selling an estimated $749K and leaving 7,836 shares worth $709K. The position accounts for 0.03% of the portfolio, ranked #90.
Skandinaviska Enskilda Banken (SEB) first reported a position in EW in Q1 2016 and has held it in 42 quarters since. The position peaked at $90.9M in Q4 2025. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Skandinaviska Enskilda Banken (SEB) held 7,836 shares of Edwards Lifesciences worth $709K as of Q2 2026.
- Skandinaviska Enskilda Banken (SEB) sold 8,946 Edwards Lifesciences shares in Q2 2026, an estimated $749K.
- Edwards Lifesciences made up 0.03% of Skandinaviska Enskilda Banken (SEB)'s portfolio in Q2 2026, its #90 holding.
- Skandinaviska Enskilda Banken (SEB) first reported a position in Edwards Lifesciences in Q1 2016 and has held it in 42 quarters since.
- Skandinaviska Enskilda Banken (SEB)'s Edwards Lifesciences position peaked at $90.9M in Q4 2025.
- 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q2 2026, filed 10 Aug 2026.